-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40

Benzinga·07/30/2026 13:42:19
语音播报
Wedbush analyst David Nierengarten maintains Damora Therapeutics (NASDAQ:DMRA) with a Outperform and raises the price target from $35 to $40.